# US 2024/0197677 A1 · Putrescine slow-release topical formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197677 A1
- Document ID: US20240197677A1
- Status: Published application
- Kind: A1
- Application number: 18/588,829
- Filed: 2024-02-27
- Published: 2024-06-20
- Earliest claimed: 2016-11-21
- Applicants: Vivier Canada Inc.
- Inventors: Ghislain VIVIER
- Web page: https://patentgrep.com/patent/US20240197677A1

## CPC

- A61K 31/375: Ascorbic acid, i.e. vitamin C; Salts thereof
- A61K 8/345: {containing more than one hydroxy group}
- A61K 8/41: Amines
- A61K 8/416: {Quaternary ammonium compounds (A61K8/35 takes precedence)}
- A61K 8/60: Sugars; Derivatives thereof
- A61K 8/676: {Ascorbic acid, i.e. vitamin C}
- A61K 8/9789: Magnoliopsida [dicotyledons]
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 31/132: having two or more amino groups, e.g. spermidine, putrescine
- A61K 31/205: Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A61K 36/752: Citrus, e.g. lime, orange or lemon
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/186: {Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61Q 19/00: Preparations for care of the skin
- A61Q 19/007: {Preparations for dry skin}
- A61Q 19/008: {Preparations for oily skin}
- A61Q 19/08: Anti-ageing preparations
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

The present invention describes slow-release compositions for the effective delivery of active ingredients such as putrescine and Vitamin C into the skin. These compositions may be used in a variety of cosmetic and therapeutic applications including for promoting wound healing, for reducing or preventing the formation of hypertrophic scar tissue, for reducing or preventing skin irritation and inflammation and/or for reducing or preventing skin's signs of aging.

## Claims

### Claim 1

A slow release aqueous topical composition comprising (i) a primary polyamine; (ii) Vitamin C; (iii) ethoxydiglycol; and (iv) a glycol selected from (a) propylene glycol, (b) butylene glycol, (c) pentylene glycol, and (d) a combination of at least two of (a) to (c).

### Claim 2

A slow-release aqueous topical composition comprising (i) at least 16% w/w of vitamin C; (ii) ethoxydiglycol; and (iii) a glycol selected from (a) propylene glycol, (b) butylene glycol, (c) pentylene glycol, and (d) a combination of at least two of (a) to (c).

### Claim 3

A slow-release aqueous topical composition comprising (i) at least one active ingredient, (ii) ethoxydiglycol; (iii) a glycol selected from (a) propylene glycol, (b) butylene glycol, (c) pentylene glycol and (d) a combination of at least two of (a) to (c); and (iv) betaine and/or polysorbate 20.

### Claim 4 (depends on 3)

The topical composition of claim 3, wherein the composition comprises between about 0.5 w/w and about 3% w/w of betaine; or about 1.2% of betaine.

### Claim 5 (depends on 3)

The topical composition of claim 3, comprises between about 0.1% w/w and about 3% w/w of polysorbate 20; or about 1.3% w/w of polysorbate 20.

### Claim 6 (depends on 3)

The topical composition of claim 3, wherein (i) the at least one active ingredient comprises (a) a primary polyamine; or wherein said primary polyamine is a primary aliphatic lower-alkyl (C1-5) monoamine; a primary aliphatic alkylamine or a primary aliphatic lower-alkyl (C1-5) polyamine; or wherein said primary aliphatic lower-alkyl (C1-5) monoamine is aminoacetonitrile, said primary aliphatic alkylamine is spermine or spermidine and said primary aliphatic lower-alkyl (C1-5) polyamine is putrescine or dansylcadaverine, or wherein said primary polyamine putrescine (1,4-diaminobutane); and/or (b) a Vitamin C, and preferably L-ascorbic acid, 3-O-ethyl ascorbic acid (ETVC) or a combination thereof.

### Claim 7 (depends on 6)

The topical composition of claim 6, wherein the at least one active ingredient comprises between about 0.1% w/w to about 1% w/w of putrescine; about 0.4% w/w of putrescine; or about 0.8% w/w of putrescine.

### Claim 8 (depends on 1)

The topical composition of claim 1, wherein said composition comprises more than zero and up to about 20% w/w of 3-O-ethyl ascorbic acid (ETVC), L-ascorbic acid or a combination thereof as Vitamin C; or about 10% w/w or about 20% w/w of ETVC, L-ascorbic acid or a combination thereof as Vitamin C; or about 5% or 10% w/w of L-ascorbic acid or of ETVC; or about 5% w/w of L-ascorbic acid and 5% w/w of ETVC; or about 12.5% w/w of L-ascorbic acid and 7.5% w/w of ETVC; or about 3% w/w of L-ascorbic acid and 7% w/w ETVC.

### Claim 9 (depends on 1)

The topical composition of claim 1, wherein (a) the ethoxydiglycol concentration in the composition is of between about 22% w/w and about 60% w/w; or between about 48% w/w and about 55% w/w; or about 49% w/w; or about 43% w/w; or about 33% w/w; or about 51% w/w; or more than zero and up to 2.5%; or about 2.5%; and/or (b) the glycol comprises propylene glycol in a concentration in the composition of between about 20% w/w and about 30% w/w of propylene glycol; or between about 26% w/w and about 27.5% w/w of propylene glycol; or between about 23% w/w and about 27.5% w/w of propylene glycol; or about 27%, 26% or 23% w/w of propylene glycol.

### Claim 10 (depends on 9)

The topical composition of claim 9, wherein the glycol consists of a combination of (a) propylene glycol, (b) butylene glycol, and (c) pentylene glycol.

### Claim 11 (depends on 10)

The topical composition of claim 10, wherein (i) the concentration of propylene glycol in the composition is about 32% w/w; (ii) the concentration of butylene glycol in the composition is about 22% w/w.

### Claim 12 (depends on 10)

The topical composition of claim 10, wherein the concentration of pentylene glycol in the composition is about 22% w/w.

### Claim 13 (depends on 10)

The topical composition of claim 10, wherein the ratio of propylene glycol:butylene glycol:pentylene glycol is about 1.45:1:1 w/w.

### Claim 14 (depends on 1)

The topical composition of claim 1, wherein the composition further comprises at least one antioxidant.

### Claim 15 (depends on 14)

The topical composition of claim 14, wherein at least one antioxidant comprises a fruit extract, hydroquinone, vitamin E, a retinoid or any combination thereof.

### Claim 16 (depends on 15)

The topical composition of claim 15, wherein at least one antioxidant comprises an antioxidant fruit extract.

### Claim 17 (depends on 15)

The topical composition of claim 15, wherein the antioxidant fruit extract is a grapefruit extract.

### Claim 18 (depends on 17)

The topical composition of claim 17, comprising about 1% of grapefruit extract.

### Claim 19 (depends on 1)

The topical composition of claim 1, wherein the pH of the composition is between about 2 and about 4.

### Claim 20 (depends on 1)

Method of using the topical composition as defined claim 1, for (A) treating or preventing skin inflammation, skin irritation, and/or skin's signs of aging; (B) promoting wound healing; (C) preventing or reducing the formation of hypertrophic scar tissue; or (D) (i) increasing the thickness of the skin; (ii) increasing skin tone or preventing loosening of the skin; (iii) reducing dryness of the skin; (iv) reducing oiliness of the skin; and/or (v) preventing or reducing the appearance of fine lines and wrinkles, comprising administering the composition to a subject in need thereof.